Onera Health Onera Health develops wearable sleep diagnostics that let clinicians perform polysomnography in a patient’s home. Its Onera Sleep Test System uses self-applied sensors to record sleep-related brain, respiratory and cardiovascular signals, giving physicians comprehensive data for assessing sleep disorders. The company combines the sensor hardware with its cloud-based Onera Digital Health Platform and a PSG-as-a-Service offering to support ordering, overnight testing and clinical analysis workflows. Its aim is to make comprehensive sleep studies accessible beyond a specialist sleep laboratory while leaving diagnosis and treatment decisions with healthcare professionals. Founded in Eindhoven in 2017 as an imec spin-off, Onera operates in the Netherlands and the United States; its website identifies the legal company as Onera Technologies B.V.
Founded 2017
Drew Burdon Board appointment announced January 2024 (current status unverified) Hartmut Schneider Founder & Chief Medical Officer; Medical Advisory Board Member published June 2023 (current advisory status unverified) Ludger Grote Medical Advisory Board Member, published June 2023 (current status unverified) Michaël Vlemmix Board appointment announced January 2024 (current status unverified)
SHOW MORE
team@apexlogos.ai · 16 hours ago
Onera Health is Onera Technologies B.V., an Eindhoven diagnostic company founded2017; unrelated native Sonera and French aerospace ONERA are preserved. Own current management directory publishes six leaders, supplemented with explicitly published communications staff and chair/board/advisory affiliations. Medical Advisory Board was announced June1,2023; Ludger Grote and Hartmut Schneider advisory currentness remains unverified, with historical wording. David P. White advisory affiliation is reaffirmed January12,2026, distinct from Oxford digital officer DavidWhite. Drew Burdon and Michaël Vlemmix board appointments are published in the January16,2024 transaction release, not independently proven current; dates/end dates are not invented. Tom Vanhoutte is explicitly a director in own live presskit. Maria Sainz own January9,2025 chair announcement supports reuse of the verified Hyperfine executive identity. RoundEUR30m body amount is independently confirmed by Gimv and Invest-NL, while headline says overEUR30m; USD32m is conversion, not another financing. EQT’s HE3 attribution is explicit; fresh native review confirms canonical fund61J43NPXS11YS7RBA89HE1YF3P6AHR8F belongs to EQTLifeSciences. Fund provenance is recorded here without inventing an investor ticket or another fund vehicle. Actual EQT9731 participation included, ticket unknown; Invest-NL actualEUR5m ticket sourced separately. BOM is named in round but lacks a native exact manager identity; omitted from strict participation operations pending full profile. Jazz Pharmaceuticals is listed as a current investor in presskit but is not a named SeriesC participant, so no2024 Jazz cheque is inferred. Authentic company presskit logo downloaded unaltered and visually inspected. Sources: https://www.onerahealth.com/newsroom-articles/onera-raises-series-c ; https://www.invest-nl.nl/en/news/investment-leads-to-accessible-sleep-research-and-reduced-healthcare-costs ; https://www.onerahealth.com/presskit-onera ; https://www.onerahealth.com/newsroom-articles/onera-launches-medical-advisory-board ; https://onerahealth.com/newsroom-articles/new-clinical-study-publication-validates-respiratory-outcomes ; https://www.onerahealth.com/newsroom-articles/onera-health-appoints-maria-sainz-as-chair-of-the-board SHOW MORE
Maria SainzChair of the Board